Evidence map›Paper›PMID 41992894›Full record

ArticleJournal of veterinary pharmacology and therapeutics2026

Pharmacokinetics of Moxidectin in Bare-Nosed Wombats (Vombatus ursinus) After Intravenous, Sub-Cutaneous and Transdermal Administration.

E K Stott, L F Skerratt, T Whittem, M Leeming, K Pillay, G S Doran, B Gardner, M Lynch, M Klein, P Holz and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

E K StottFaculty of Science, Melbourne Veterinary School, The University of Melbourne, Werribee, Victoria, Australia.ORCID https://orcid.org/0000-0003-3818-9411
L F SkerrattFaculty of Science, Melbourne Veterinary School, The University of Melbourne, Werribee, Victoria, Australia.
T WhittemCollege of Science and Engineering, James Cook University, Townsville, Australia.
M LeemingBio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia.
K PillaySydney Zoo, Bungaribee, New South Wales, Australia.
G S DoranSchool of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
B GardnerFaculty of Science, Melbourne Veterinary School, The University of Melbourne, Werribee, Victoria, Australia.
M LynchFaculty of Science, Melbourne Veterinary School, The University of Melbourne, Werribee, Victoria, Australia.
M KleinAustralian Synchrotron/ANSTO, Clayton, Victoria, Australia.
P HolzFaculty of Science, Melbourne Veterinary School, The University of Melbourne, Werribee, Victoria, Australia.
T ChenFaculty of Science, Melbourne Veterinary School, The University of Melbourne, Werribee, Victoria, Australia.
J HufschmidFaculty of Science, Melbourne Veterinary School, The University of Melbourne, Werribee, Victoria, Australia.ORCID https://orcid.org/0000-0001-9427-7702
A P WoodwardFaculty of Health, University of Canberra, Bruce, Australia.

Funding

Australian Government Research Training Program ScholarshipErnie Stewart Memorial Research GrantMange Management VictoriaNew South Wales Department of Climate Change, Energy, Environment and Water
6 · The paper itself

Abstract

The anti-parasitic drug moxidectin is a frontline treatment for sarcoptic mange in bare-nosed wombats (Vombatus ursinus), a disease causing significant animal welfare issues and instances of local population declines. Despite widespread usage, knowledge of species-specific pharmacokinetics of moxidectin in bare-nosed wombats is still limited. This study describes the clinical pharmacokinetics of moxidectin by intravenous, subcutaneous, and transdermal routes of administration in bare-nosed wombats. Plasma moxidectin concentration was assessed by liquid chromatography mass spectrometry and analysed by Bayesian hierarchical modelling. Plasma clearance was 1.11-1.85 mL/min/kg. The subcutaneous route showed biphasic absorption, dominated by a slow terminal absorption phase (80% of the effective dose of moxidectin was absorbed in this phase) with a half-life of approximately 631 h (26.3 days). The transdermal route had an estimated half-life of 21.78 h (1308) min. The average bioavailability was 0.59% and 95.7% by the transdermal and subcutaneous route, respectively. This detailed insight into the pharmacokinetics of moxidectin in bare-nosed wombats provides a crucial foundation for the design of treatment regimens, whilst also highlighting the inefficiency of transdermal delivery.

Indexed as

Antiparasitic AgentsMacrolidesMarsupialiaAdministration, CutaneousAnimalsArea Under CurveFemaleHalf-LifeInjections, IntravenousInjections, SubcutaneousMaleAntiparasitic AgentsMacrolidesmoxidectinBayesianone healthpharmacometricssarcoptic mangewildlife disease

Identifiers

PMID41992894
PMCPMC13552517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.